EMAIL THIS PAGE TO A FRIEND

Lijecnicki vjesnik

[Histrelin acetate--the first once yearly LHRH agonist].


PMID 22165080

Abstract

Long-acting synthetic luteinising hormone-releasing hormone agonists have become the mainstay for androgen-deprivation therapy, because they avoid the physical and psychological discomfort associated with orchidectomy and lack the potential cardiotoxicity associated with estrogens such as diethylstilbestrol. Currently available luteinising hormone-releasing hormone agonist analogues include leuprolide, goserelin, triptorelin, degarelix and buserelin were administered as either intramuscular or subcutaneous depot injections on a 1, 2, 3 or 6 months basis. Histrelin acetate is the first long-acting luteinising hormone-releasing hormone agonist available as a once-yearly subcutaneous implant.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

L2761
[des-Gly10, D-His(Bzl)6]-LH-RH ethylamide, ≥97% (HPLC), powder
C66H86N18O12